Santiago Alvarez-Arango
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Santiago Alvarez-Arango has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Donald MacGlashan
Division of Allergy and Clinical Immunology, Department of Medicine Johns Hopkins University Baltimore Maryland USA
4 shared publications Anum F. Muzaffar
Division of Allergy and Clinical Immunology, Department of Pediatrics
3 shared publicationsKimberly G. Blumenthal
Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, Fla; The Mongan Institute, Massachusetts General Hospital, Boston, Mass
3 shared publicationsMelanie C. Dispenza
Division of Allergy and Clinical Immunology, Department of Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA
3 shared publications- Elina Jerschow
Division of Allergic Diseases, Department of Medicine Mayo Clinic Rochester Minnesota USA
2 shared publications - Elizabeth Jane Phillips
Vanderbilt University, Nashville, Tennessee, USA
2 shared publications
Latest Publications
- 10 November 2026
- Published by Wiley in Clinical & Experimental Allergy
Vancomycin Exposure Does Not Elicit Detectable Vancomycin‐Specific IgG
Summary: Vancomycin‐specific IgG was undetectable in exposed subjects with or without prior reaction, suggesting that vancomycin is poorly immunogenic. Absence of drug‐specific antibody does not imply a milder reaction or lower clinical risk.
- 10 November 2026
- Published by Wiley in Clinical & Experimental Allergy
Vancomycin Exposure Does Not Elicit Detectable Vancomycin‐Specific IgG
Summary: Vancomycin‐specific IgG was undetectable in exposed subjects with or without prior reaction, suggesting that vancomycin is poorly immunogenic. Absence of drug‐specific antibody does not imply a milder reaction or lower clinical risk.
- 6 May 2026
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (5) , 1034-1047
Redefining Diagnostic and Management Approaches to Vancomycin Adverse Drug Reactions
- 6 May 2026
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (5) , 1034-1047
Redefining Diagnostic and Management Approaches to Vancomycin Adverse Drug Reactions
- 1 March 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (5) , 990-999
Insulin Allergy: The Allergist’s Updated Approach to Evaluation and Management
- 1 March 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (5) , 990-999
Insulin Allergy: The Allergist’s Updated Approach to Evaluation and Management
- 17 November 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (1) , 75-83
Defining Optimal Basophil Passive Sensitisation Parameters
Background: Detecting drug‐specific IgE (sIgE) is crucial for diagnosing immediate drug‐induced hypersensitivity reactions. Basophil activation tests serve as a method to determine the presence of drug‐sIgE, highlighting the importance of optimising the assay. Optimisation involves considering multiple factors to ensure sensitisation helps detect an antigen sIgE. The study investigates the complex factors influencing basophil responsiveness thresholds and aims to provide rules‐of‐thumb guidance for expected results.Methods: Open and occupied FcεRI receptors were analysed by flow cytometry pre‐ and postdissociation of surface‐bound sIgE. Basophils were then sensitised with serial concentrations of penicillin (BPO)‐sIgE in serum or buffer and incubated for 1, 4 and 18 h with or without D2O and/or IL‐3. Basophil sensitivity was evaluated based on FcεRI receptor densities, sIgE/total IgE (tIgE) ratios, responses to BPO(21)‐HSA, and D2O and/or IL‐3 effects, with maximal responses determined using anti‐IgE human antibodies. These optimised conditions were tested with peanut‐sIgE and cat‐sIgE sera.Results: Basophils from five donors were used. The FcεRI receptor expression initially averaged 155,000/cell (47,000–344,000/cell), with 35% (5%–79%) unoccupied, which postdissociation increased to 98% (82%–100%) unoccupied. Upon sensitisation, the average reloading with BPO‐sIgE was 39% (33%–48%). The ED50 (a measure of cellular sensitivity) was approx. 6000 BPO‐sIgE/cell, and the average maximal anti‐IgE antibody response was 58% (25%–68%). A 4‐h sensitisation at 4°C with IL‐3 pretreatment and 70% D2O allowed the detection of BPO‐sIgE/tIgE ratios as low as 0.02%–0.05% without spontaneous histamine release. Under the same conditions, responses were detected with 0.33% peanut‐sIgE and 0.1% cat‐sIgE ratios.Conclusion: This study outlines a method to assess basophil sensitisation, emphasising the minimum sIgE/tIgE ratio needed for basophil responsiveness. It considers factors like FcεRI open/unoccupied FcεRI receptors, sIgE/tIgE ratios and the effect of D2O and IL‐3. This sets a strong foundation for refining and advancing basophil activation functional assays.
- 17 November 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (1) , 75-83
Defining Optimal Basophil Passive Sensitisation Parameters
Background: Detecting drug‐specific IgE (sIgE) is crucial for diagnosing immediate drug‐induced hypersensitivity reactions. Basophil activation tests serve as a method to determine the presence of drug‐sIgE, highlighting the importance of optimising the assay. Optimisation involves considering multiple factors to ensure sensitisation helps detect an antigen sIgE. The study investigates the complex factors influencing basophil responsiveness thresholds and aims to provide rules‐of‐thumb guidance for expected results.Methods: Open and occupied FcεRI receptors were analysed by flow cytometry pre‐ and postdissociation of surface‐bound sIgE. Basophils were then sensitised with serial concentrations of penicillin (BPO)‐sIgE in serum or buffer and incubated for 1, 4 and 18 h with or without D2O and/or IL‐3. Basophil sensitivity was evaluated based on FcεRI receptor densities, sIgE/total IgE (tIgE) ratios, responses to BPO(21)‐HSA, and D2O and/or IL‐3 effects, with maximal responses determined using anti‐IgE human antibodies. These optimised conditions were tested with peanut‐sIgE and cat‐sIgE sera.Results: Basophils from five donors were used. The FcεRI receptor expression initially averaged 155,000/cell (47,000–344,000/cell), with 35% (5%–79%) unoccupied, which postdissociation increased to 98% (82%–100%) unoccupied. Upon sensitisation, the average reloading with BPO‐sIgE was 39% (33%–48%). The ED50 (a measure of cellular sensitivity) was approx. 6000 BPO‐sIgE/cell, and the average maximal anti‐IgE antibody response was 58% (25%–68%). A 4‐h sensitisation at 4°C with IL‐3 pretreatment and 70% D2O allowed the detection of BPO‐sIgE/tIgE ratios as low as 0.02%–0.05% without spontaneous histamine release. Under the same conditions, responses were detected with 0.33% peanut‐sIgE and 0.1% cat‐sIgE ratios.Conclusion: This study outlines a method to assess basophil sensitisation, emphasising the minimum sIgE/tIgE ratio needed for basophil responsiveness. It considers factors like FcεRI open/unoccupied FcεRI receptors, sIgE/tIgE ratios and the effect of D2O and IL‐3. This sets a strong foundation for refining and advancing basophil activation functional assays.
- 7 October 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (10) , 2809-2810
First-Line Anti-Tuberculosis Drug-Related DRESS Syndrome Challenges: Management Strategies in Patients With HIV-TB Coinfection
- 7 October 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (10) , 2809-2810
First-Line Anti-Tuberculosis Drug-Related DRESS Syndrome Challenges: Management Strategies in Patients With HIV-TB Coinfection
- 19 August 2024
- Published by Wolters Kluwer Health in Current Opinion in Pediatrics
- Vol. 36 (6) , 674-683
Non-IgE-mediated drug-induced hypersensitivity reactions in pediatrics
Purpose of review: Despite their prevalence and potential severity, non-IgE-mediated drug-induced hypersensitivity reactions (DHRs) are under-researched and poorly defined, particularly in children. Presentations range from mild cutaneous reactions to severe systemic diseases, with pathophysiological mechanisms and reliable diagnostic markers not well established. The lack of validated tests often leads to permanent drug restrictions, reliance on second-line drugs, and increased costs. Focusing on recent advancements and areas needing further research, this review aims to enhance children's recognition, diagnosis, and management of non-IgE-mediated DHRs. Recent findings: Recent studies have enhanced the understanding of immediate and delayed non-IgE-mediated drug reactions. Key findings include the Mas-related G protein-coupled receptor X2 in mast cells and the identification of HLA alleles linked to severe cutaneous adverse reactions, such as Stevens–Johnson syndrome and toxic epidermal necrolysis. Improved diagnostic techniques, including skin testing, show promise in identifying immediate and delayed non-IgE DHRs. Additionally, research highlights the impact of cofactors, drug metabolites, and co-infections on these DHRs and explores potential biomarkers for predicting reaction severity. Summary: Non-IgE-mediated DHRs are a significant cause of morbidity and treatment changes in pediatric patients. Recent research underscores their clinical presentations and mechanisms, paving the way for more precise diagnostic and therapeutic strategies to improve patient outcomes.
- 19 August 2024
- Published by Wolters Kluwer Health in Current Opinion in Pediatrics
- Vol. 36 (6) , 674-683
Non-IgE-mediated drug-induced hypersensitivity reactions in pediatrics
Purpose of review: Despite their prevalence and potential severity, non-IgE-mediated drug-induced hypersensitivity reactions (DHRs) are under-researched and poorly defined, particularly in children. Presentations range from mild cutaneous reactions to severe systemic diseases, with pathophysiological mechanisms and reliable diagnostic markers not well established. The lack of validated tests often leads to permanent drug restrictions, reliance on second-line drugs, and increased costs. Focusing on recent advancements and areas needing further research, this review aims to enhance children's recognition, diagnosis, and management of non-IgE-mediated DHRs. Recent findings: Recent studies have enhanced the understanding of immediate and delayed non-IgE-mediated drug reactions. Key findings include the Mas-related G protein-coupled receptor X2 in mast cells and the identification of HLA alleles linked to severe cutaneous adverse reactions, such as Stevens–Johnson syndrome and toxic epidermal necrolysis. Improved diagnostic techniques, including skin testing, show promise in identifying immediate and delayed non-IgE DHRs. Additionally, research highlights the impact of cofactors, drug metabolites, and co-infections on these DHRs and explores potential biomarkers for predicting reaction severity. Summary: Non-IgE-mediated DHRs are a significant cause of morbidity and treatment changes in pediatric patients. Recent research underscores their clinical presentations and mechanisms, paving the way for more precise diagnostic and therapeutic strategies to improve patient outcomes.
- 6 August 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (11) , 3025-3033.e6
A Skin Testing Strategy for Non–IgE-Mediated Reactions Associated With Vancomycin
- 6 August 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (11) , 3025-3033.e6
A Skin Testing Strategy for Non–IgE-Mediated Reactions Associated With Vancomycin
- 28 February 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (5) , 1109-1119
Non–IgE-Mediated Immediate Drug-Induced Hypersensitivity Reactions
- 28 February 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (5) , 1109-1119
Non–IgE-Mediated Immediate Drug-Induced Hypersensitivity Reactions
- Open Access
- 21 February 2024
- Published by Frontiers Media SA in Frontiers in Allergy
- Vol. 5, 1357901
A case report and systematic literature review: insulin-induced type III hypersensitivity reaction
Insulin-induced type III hypersensitivity reactions (HSRs) are exceedingly rare and pose complex diagnostic and management challenges. We describe a case of a 43-year-old woman with type 1 diabetes mellitus (DM), severe insulin resistance, and subcutaneous nodules at injection sites, accompanied by elevated anti-insulin IgG autoantibodies. Treatment involved therapeutic plasma exchange (TPE) and intravenous immunoglobulin (IVIg) as bridge therapy, followed by long-term immunosuppression, which reduced autoantibody levels and improved insulin tolerance. Given the limited treatment guidelines, we conducted a comprehensive literature review, identifying 16 similar cases. Most patients were females with a median age of 36.5 years; 63% had type 1 DM, and 44% had concurrent insulin resistance (56% with elevated autoantibodies). Treatment approaches varied, with glucocorticoids used in 67% of cases. Patients with type 1 DM were less responsive to steroids than those with type 2 DM, and had a more severe course. Of those patients with severe disease necessitating immunosuppression, 66% had poor responses or experienced relapses. The underlying mechanism of insulin-induced type III HSRs remains poorly understood. Immunosuppressive therapy reduces anti-insulin IgG autoantibodies, leading to short-term clinical improvement and improved insulin resistance, emphasizing their crucial role in the condition. However, the long-term efficacy of immunosuppression remains uncertain and necessitates continuous evaluation and further research.
- 21 February 2024
- Published by Frontiers Media SA in Frontiers in Allergy
- Vol. 5, 1357901
Open AccessA case report and systematic literature review: insulin-induced type III hypersensitivity reaction
Insulin-induced type III hypersensitivity reactions (HSRs) are exceedingly rare and pose complex diagnostic and management challenges. We describe a case of a 43-year-old woman with type 1 diabetes mellitus (DM), severe insulin resistance, and subcutaneous nodules at injection sites, accompanied by elevated anti-insulin IgG autoantibodies. Treatment involved therapeutic plasma exchange (TPE) and intravenous immunoglobulin (IVIg) as bridge therapy, followed by long-term immunosuppression, which reduced autoantibody levels and improved insulin tolerance. Given the limited treatment guidelines, we conducted a comprehensive literature review, identifying 16 similar cases. Most patients were females with a median age of 36.5 years; 63% had type 1 DM, and 44% had concurrent insulin resistance (56% with elevated autoantibodies). Treatment approaches varied, with glucocorticoids used in 67% of cases. Patients with type 1 DM were less responsive to steroids than those with type 2 DM, and had a more severe course. Of those patients with severe disease necessitating immunosuppression, 66% had poor responses or experienced relapses. The underlying mechanism of insulin-induced type III HSRs remains poorly understood. Immunosuppressive therapy reduces anti-insulin IgG autoantibodies, leading to short-term clinical improvement and improved insulin resistance, emphasizing their crucial role in the condition. However, the long-term efficacy of immunosuppression remains uncertain and necessitates continuous evaluation and further research.